Progress in standards for reporting omics data.
A number of research groups are generating standard mechanisms and prescriptions for reporting various kinds of biological and biomedical experiments. The motives for this generation include concern about the longevity of data sets (and the robustness of conclusions built upon them), the desire to integrate data from diverse scientific disciplines, and the facility to productively mine accrued data. The pharmaceutical industry continues to play a significant role in the genesis and development of such standards, in conjunction with technology vendors and academia. This review describes the context and nature of the new candidate standards and discusses their relevance to drug discovery and development.
Taylor
Chris F
CF
European Bioinformatics Institute, Hinxton, Cambridgeshire CB10 1SD, UK. chris.taylor@ebi.ac.uk
D000818:Animals; D035843:Biomedical Research / Q000379:methods / Q000592:standards* / Q000639:trends; D016208:Databases, Factual / Q000592:standards*; D023281:Genomics / Q000592:standards; D019983:Guideline Adherence; D017408:Guidelines as Topic; D006801:Humans; D033181:Information Dissemination; D010599:Pharmacokinetics; D040901:Proteomics / Q000592:standards; D012984:Software; D049490:Systems Biology / Q000379:methods / Q000592:standards* / Q000639:trends; D018511:Systems Integration; D013678:Technology, Pharmaceutical / Q000379:methods / Q000592:standards* / Q000639:trends; D018875:Vocabulary, Controlled